Related references
Note: Only part of the references are listed.Indospicine combined with arginine deprivation triggers cancer cell death via caspase-dependent apoptosis
Galyna Y. Shuvayeva et al.
CELL BIOLOGY INTERNATIONAL (2021)
Knockdown of Enhancer of Zeste Homolog 2 Affects mRNA Expression of Genes Involved in the Induction of Resistance to Apoptosis in MOLT-4 Cells
Adel Naimi et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2020)
Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism
Vesna Vetma et al.
CELL DEATH AND DIFFERENTIATION (2020)
Mesenchymal stem cells engineered by modified polyethylenimine polymer for targeted cancer gene therapy, in vitro and in vivo
Zahra Salmasi et al.
BIOTECHNOLOGY PROGRESS (2020)
Arginine deprivation: a potential therapeutic for cancer cell metastasis? A review
Houssam Al-Koussa et al.
CANCER CELL INTERNATIONAL (2020)
Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells
Zina Sarif et al.
MOLECULAR CARCINOGENESIS (2020)
Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression
Stephanie S. Kim et al.
THERANOSTICS (2020)
Decreasing the immunogenicity of arginine deiminase enzyme via structure-based computational analysis
Mahboubeh Zarei et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2019)
Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy
Javier Naval et al.
CANCERS (2019)
Promotion of TRAIL/Apo2L-induced apoptosis by low-dose interferon-β in human malignant melanoma cells
Akira Kazaana et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Metabolic pathways of L-arginine and therapeutic consequences in tumors
Jaroslaw Szefel et al.
ADVANCES IN MEDICAL SCIENCES (2019)
A TRAIL-Delivered Lipoprotein-Bioinspired Nanovector Engineering Stem Cell-Based Platform for Inhibition of Lung Metastasis of Melanoma
Kerong Chen et al.
THERANOSTICS (2019)
Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy
Pedro P. G. Guimaraes et al.
ACS NANO (2018)
Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations
Matias Eliseo Melendez et al.
Oncotarget (2018)
Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model
Fazileh Hosseini Shamili et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Autophagy maintains tumour growth through circulating arginine
Laura Poillet-Perez et al.
NATURE (2018)
Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM
Justyna Magdalena Przystal et al.
CELL DEATH & DISEASE (2018)
TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase
Elena Brin et al.
Oncotarget (2018)
Arginine-Depleting Enzymes - An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies
Christin Riess et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Arginine-Dual Roles as an Onconutrient and Immunonutrient
Vance L. Albaugh et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability
M. Jeong et al.
ONCOGENE (2017)
The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma
Angkana Thongkum et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Juglone potentiates TRAIL-induced apoptosis in human melanoma cells via activating the ROS-p38-p53 pathway
Xiao Liu et al.
MOLECULAR MEDICINE REPORTS (2017)
A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor
Weitao Shen et al.
CELL DEATH & DISEASE (2017)
PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration
Elena Brin et al.
ONCOTARGET (2017)
Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers
Jeff Charles Kremer et al.
CELL REPORTS (2017)
Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression
Anke Werner et al.
FRONTIERS IN IMMUNOLOGY (2017)
Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression
Wen-Bin Tsai et al.
SCIENTIFIC REPORTS (2017)
Deciphering molecular mechanisms of arginine deiminase-based therapy - Comparative response analysis in paired human primary and recurrent glioblastomas
Claudia Maletzki et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2017)
Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts
Sze-Kwan Lam et al.
RESPIRATORY RESEARCH (2017)
Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents
W-B Tsai et al.
ONCOGENE (2016)
Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing
Y-T Oh et al.
ONCOGENE (2016)
Onto better TRAILs for cancer treatment
D. de Miguel et al.
CELL DEATH AND DIFFERENTIATION (2016)
Arginine deprivation induces endoplasmic reticulum stress in human solid cancer cells
Yaroslav Bobak et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2016)
Molecular basis and current strategies of therapeutic arginine depletion for cancer
Livingstone Fultang et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Adipose-derived mesenchymal stem cell-facilitated TRAIL expression in melanoma treatment in vitro
Hai Xia Jing et al.
MOLECULAR MEDICINE REPORTS (2016)
Arginine dependence of tumor cells: targeting a chink in cancer's armor
M. D. Patil et al.
ONCOGENE (2016)
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas
Gregory R. Bean et al.
CELL DEATH & DISEASE (2016)
Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1a, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation
Yan Long et al.
ONCOTARGET (2016)
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
Djoke Hendriks et al.
ONCOIMMUNOLOGY (2016)
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
Karianne G. Fleten et al.
CELL DEATH DISCOVERY (2016)
Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo
Tomas Fiedler et al.
CANCER BIOLOGY & THERAPY (2015)
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
Yan Liu et al.
CLINICAL CANCER RESEARCH (2015)
Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors
Benjamin K. Tomlinson et al.
CLINICAL CANCER RESEARCH (2015)
The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma
Mario Venza et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Sensitization of Melanoma Cells for Death Ligand TRAIL Is Based on Cell Cycle Arrest, ROS Production, and Activation of Proapoptotic BcI-2 Proteins
Sandra-Annika Quast et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1
Shuyu Wang et al.
SCIENCE (2015)
UPR, autophagy, and mitochondria crosstalk underlies the ER stress response
Daniela Senft et al.
TRENDS IN BIOCHEMICAL SCIENCES (2015)
Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin
Niramol Savaraj et al.
ONCOTARGET (2015)
L-Arginine Depletion Blunts Antitumor T-cell Responses by Inducing Myeloid-Derived Suppressor Cells
Matthew Fletcher et al.
CANCER RESEARCH (2015)
TNF-related Apoptosis-inducing Ligand Delivered by rNDV is a Novel Agent for Cancer Gene Therapy
Fu-Liang Bai et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2015)
Involvement of autophagy in recombinant human arginase-induced cell apoptosis and growth inhibition of malignant melanoma cells
Ziyu Wang et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2014)
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling
Jiangbo Liu et al.
BMC CANCER (2014)
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
J. Lemke et al.
CELL DEATH AND DIFFERENTIATION (2014)
Sensitization of melanoma cells for TRAIL-induced apoptosis by activation of mitochondrial pathways via Bax
Sandra-Annika Quast et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2014)
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer
Rouzbeh Daylami et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway
Ali R. Jazirehi et al.
JOURNAL OF IMMUNOLOGY (2014)
RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells
Anja Berger et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy
Chun A. Changou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Arginine Starvation Impairs Mitochondrial Respiratory Function in ASS1-Deficient Breast Cancer Cells
Fuming Qiu et al.
SCIENCE SIGNALING (2014)
Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells
Z. Wang et al.
CELL DEATH & DISEASE (2014)
ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance
Hsuan-Ying Huang et al.
CLINICAL CANCER RESEARCH (2013)
TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation
Min You et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2013)
Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction
Yan Long et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Nutrient signaling to mTOR and cell growth
Jenna L. Jewell et al.
TRENDS IN BIOCHEMICAL SCIENCES (2013)
ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis
S-A Quast et al.
CELL DEATH & DISEASE (2013)
Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax
A. Berger et al.
CELL DEATH & DISEASE (2013)
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma
N. Syed et al.
CELL DEATH & DISEASE (2013)
Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase
M. P. Kelly et al.
BRITISH JOURNAL OF CANCER (2012)
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
L. G. Feun et al.
BRITISH JOURNAL OF CANCER (2012)
Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells
Wen-Bin Tsai et al.
CANCER RESEARCH (2012)
Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis
B. Delage et al.
CELL DEATH & DISEASE (2012)
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells
Antonella Manca et al.
ONCOLOGY REPORTS (2011)
Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis
Tin-Lun Lam et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
ER Stress and Its Functional Link to Mitochondria: Role in Cell Survival and Death
Jyoti D. Malhotra et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2011)
The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines
Min You et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
T-S Yang et al.
BRITISH JOURNAL OF CANCER (2010)
Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma
N. Savaraj et al.
CURRENT MOLECULAR MEDICINE (2010)
Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma
Evan S. Glazer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Amino acid regulation of TOR complex 1
Joseph Avruch et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Mechanisms and Implications of Reactive Oxygen Species Generation During the Unfolded Protein Response: Roles of Endoplasmic Reticulum Oxidoreductases, Mitochondrial Electron Transport, and NADPH Oxidase
Celio X. C. Santos et al.
ANTIOXIDANTS & REDOX SIGNALING (2009)
Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)
Sam-Mui Tsui et al.
CANCER CELL INTERNATIONAL (2009)
Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest
T. L. Lam et al.
CANCER LETTERS (2009)
Arginine Deiminase as a Novel Therapy for Prostate Cancer Induces Autophagy and Caspase-Independent Apoptosis
Randie H. Kim et al.
CANCER RESEARCH (2009)
Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer
Linda J. Nicholson et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1 alpha/Sp4
Wen-Bin Tsai et al.
MOLECULAR CANCER THERAPEUTICS (2009)
TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Anita C. Bellail et al.
REVIEWS ON RECENT CLINICAL TRIALS (2009)
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase
Tawnya L. Bowles et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin
Caroline Hilmi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis
P. Geserick et al.
ONCOGENE (2008)
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL
S. I. Bae et al.
ONCOGENE (2008)
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
Klaus W. Wagner et al.
NATURE MEDICINE (2007)
Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-κB but is related to downregulation of initiator caspases and DR4
B. M. Kurbanov et al.
ONCOGENE (2007)
Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation
A. Hamai et al.
ONCOGENE (2006)
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion
Peter W. Szlosarek et al.
CLINICAL CANCER RESEARCH (2006)
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies
PA Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Autophagy is required for maintenance of amino acid levels and protein synthesis under nitrogen starvation
J Onodera et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Expression of TRAIL and TRAIL receptors in normal and malignant tissues
RA Daniels et al.
CELL RESEARCH (2005)
Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis
C Xiao et al.
EXPERIMENTAL CELL RESEARCH (2005)
Regulation of apoptosis proteins in cancer cells by ubiquitin
HG Zhang et al.
ONCOGENE (2004)
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers - A method for identifying cancers sensitive to arginine deprivation
BJ Dillon et al.
CANCER (2004)
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis
M Chawla-Sarkar et al.
CELL DEATH AND DIFFERENTIATION (2004)
Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells
EJ Noh et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival
LB Pritzker et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: Results from phase I/II studies
F Izzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Following a TRAIL: Update on a ligand and its five receptors
FC Kimberley et al.
CELL RESEARCH (2004)
Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth
IS Park et al.
BRITISH JOURNAL OF CANCER (2003)
Apo2L/TRAIL and its death and decoy receptors
HN LeBlanc et al.
CELL DEATH AND DIFFERENTIATION (2003)
Recombinant arginine deiminase as a potential anti-angiogenic agent
K Beloussow et al.
CANCER LETTERS (2002)
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8.
FC Kischkel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
How melanoma cells evade trail-induced apoptosis
P Hersey et al.
NATURE REVIEWS CANCER (2001)
Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer
S Fulda et al.
ONCOGENE (2001)
ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas
D Vucic et al.
CURRENT BIOLOGY (2000)
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
FC Kischkel et al.
IMMUNITY (2000)
Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis
H Gong et al.
LEUKEMIA (2000)
Share Paper
